Domain Summary
Objective
To evaluate whether the use of beta-blockers in the acute phase of care improves long-term neurologic functional outcomes in critically ill patients with TBI.
Population
Adult patients admitted to the ICU following an acute moderate or severe TBI.
Primary Endpoint
Glasgow Outcome Scale extended (GOSe) at 6 months.
Secondary Endpoints
Hospital Stay
- All-cause mortality
- Myocardial ischemic events
At day 28
- Organ support free days
- Ventilator-free days
- ICU-free days
- Expected ICU events
- Serious adverse events (SAE)
At 6 months
- Quality of life (EQ-5D-5L)
- Cognition T-Montréal Cognitive Assessment test [T-MoCA])
- Depression (PHQ-9)
- All-cause mortality
Eligibility criteria
- Adult patients (≥ 18 years old)
- Acute moderate or severe acute TBI (GCS ≤12)
- No contraindication to beta-blockers
- No decision to withdraw life-sustaining therapies has been made
Interventions
Participants will be randomized to receive either beta-blockers or standard care during their ICU stay. The intervention will be administered from the time of randomization until ICU discharge, death, or a decision to withdraw life-sustaining therapies. Continuation of the intervention beyond ICU discharge will be left to the discretion of the medical team and be captured in our data collection.
Target Sample Size
Adapted based on pre-determined criteria defining superiority and futility.